Altered excitatory and inhibitory amino acid receptor binding in hippocampus of patients with temporal lobe epilepsy

Annals of Neurology

Volumn 29, Issue 5, 1991, Pages 529-541

  McDonald, John W ^a   Garofalo, Elizabeth A ^a   Hood, Terry ^a   Sackellares, J Chris ^a   Gilman, Sid ^a   McKeever, Paul E ^a   Troncoso, Juan C ^b   Johnston, Michael V ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR; FLUNITRAZEPAM; GLYCINE; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID; PHENCYCLIDINE; QUISQUALIC ACID;

ADULT; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DIAGNOSIS; EPILEPSY; ETIOLOGY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; NEUROSURGERY; PRIORITY JOURNAL; RECEPTOR BINDING; SURGERY; TEMPORAL LOBE;

ADULT; AMINO ACIDS; EPILEPSY, TEMPORAL LOBE; FEMALE; GLYCINE; HIPPOCAMPUS; HUMAN; MALE; MIDDLE AGE; OXADIAZOLES; PHENCYCLIDINE; RECEPTORS, AMINO ACID; RECEPTORS, AMPA; RECEPTORS, CELL SURFACE; RECEPTORS, GABA-A; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, PHENCYCLIDINE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025897478     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410290513     Document Type: Article

References (84)

1. Convulsant drugs, anticonvulsants and GABA‐mediated neuronal inhibition
2. Epilepsy and antiepileptic drugs: a speculative synthesis
3. GABA and the anticonvulsant action of benzodiazepine and barbiturates
4. Biochemical evidence for the alterations of GABA‐mediated synaptic transmission in pathological brain tissue (stereo EEG or morphological definition) from epileptic patients
5. The GABA postsynaptic membrane receptorionophore complex: site of action of convulsant and anticonvulsant drugs
6. Role of the gammaaminobutyric acid receptor complex in seizure disorders
7. GABA‐related phenomena, models of nervous system function and seizures
8. The GABA hypothesis of kindling: recent assay studies
9. On the role of seizure activity and endogenous excitatory amino acids in mediating seizure‐associated hippocampal damage
10. Biochemistry and basic mechanisms of epilepsy
11. Excitatory transmitters and epilepsy‐related brain damage
12. Calcium loading of mitochondria in ischemia and status epilepticus: its reversibility and significance for pathological outcome
13. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters
14. Anatomical organization of excitatory amino acid receptors and their pathways
15. Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system
16. Pharmacology of the glutamate receptor
17. Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells
18. Acute dendrotoxic changes in the hippocampus of kainate treated rats
19. “Epileptic” brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute electrophysiological and light microscopic studies
20. “Epileptic” brain damage in rats induced by sustained electrical stimulation of the perforant path. II. Ultrastructural analysis of acute hippocampal pathology
21. “Epileptic” brain damage is replicated qualitatively in the rat hippocampus by central injection of glutamate or aspartate but not by GABA or acetylcholine
22. Epilepsy and the temporal lobes. A clinical, electroencephalographic and neuropathological study of the brain in epilepsy, with particular reference to the temporal lobes
23. Epilepsy
24. The hippocampaldentate complex in temporal lobe epilepsy
25. Hippocampal neuron loss in epilepsy and after experimental seizures
26. Anticonvulsant action of excitatory amino acid antagonists
27. Protection against chemically induced seizures by 2‐amino‐7‐phosphonoheptanoic acid
28. Phencyclidine and ketamine protect against kainic acid‐induced seizure related damage
29. Pharmacological modification of amygdaloid‐kindled seizures
30. Phencyclidine inhibition of the rate of kindling development
31. Anticonvulsant action of a non‐competitive antagonist of NMDA receptors (MK‐801) in the kindling model of epilepsy
32. Anticonvulsant and antiepileptogenic actions of MK‐801 in the kinding and electroshock models
33. The NMDA‐receptor antagonist, MK‐801, suppresses limbic kindling and kindled seizures
34. Amino acid content of epileptogenic human brain: focal versus surrounding regions
35. Bursting in human epileptogenic neocortex is depressed by an N‐methyl‐D‐aspartate antagonist
36. Excitatory amino acids are elevated in human epileptic cerebral cortex
37. Neurotransmitter glutamate: its clinical importance
38. Excitatory amino acids in the brainfocus on NMDA receptors
39. GABA‐benzodiazepine‐barbiturate receptor interactions
40. Autoradiographic characterization of N‐methyl‐D‐aspartate, quisqualate‐ and kainate‐sensitive glutamate binding sites
41. 3H‐TCP‐labeled receptors in rat brain
42. 3H]glycine binding sites in rat brain by quantitative receptor autoradiography
43. Magnesium ions increase binding affinity of dissociative anesthetic receptors but not of NMDA receptors in rat brain
44. 3H]glutamate binding sites in rat brain as determined by quantitative autoradiography
45. 3H]muscimol binding in substantia nigra, endopeduncular nucleus, globus pallidus and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography
46. Quantitative autoradiography of neurotransmitter receptors in Huntington's disease
47. Benzodiazepine receptors in early Huntington's disease
48. Radiohistochemical demonstration of altered quisqualate and N‐methyl‐D‐aspartate receptor/channel binding in epileptic human hippocampi
49. MK‐801 pretreatment enhances NMDA‐mediated brain injury and increases brain NMDA recognition site binding in rats
50. N‐methyl‐D‐aspartate receptor plasticity in kindling; quantitative and qualitative alterations in the N‐methyl‐D‐aspartate receptor‐channel complex
51. NMDA receptor losses in putamen from patients with Huntington's disease
52. Non‐competitive antagonists of excitatory amino acid receptors
53. 3H] glutamate binding
54. Density and distributon of NMDA receptors in the human hippocampus in Alzheimer's disease
55. N‐methyl‐D‐aspartate receptors in the cortex and hippocampus of baboon
56. Selective reinnervation of hippocampal area CA1 and fascia dentata after destruction of CA3‐CA4 afferents with kainic acid
57. Evidence of functional mossy fiber sprouting in hippocampal formation of kainic acid treated rats
58. Synaptic reorganization in the hippocampus induced by abnormal functional activity
59. Neuropathologic changes and neuronal plasticity in temporal lobe‐limbic epilepsy
60. The role of neuronal plasticity in epilepsy
61. Hippocampal interneuron loss and piasticity in human temporal lobe epilepsy
62. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development
63. Acetylcholine, GABA, benzodiazepine and glutamate receptors in the temporal lobe of epileptic patients
64. Altered distribution of excitatory amino acid receptors in temporal lobe epilepsy
65. 3H]kainic acid binding sites
66. 3H]TCP binding in Alzheimer's disease
67. 3H]MK‐801 binding in the normal aged human hippocampus
68. Linkage between phencyclidine (PCP)and N‐methyl‐D‐aspartate (NMDA) receptors in the cerebellum
69. Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists
70. 3H]TCP binding in rat cortical membranes
71. Loss of glycinedependent radioligand binding to the N‐methyl‐D‐aspartate‐phencyclidine receptor complex in patients with Alzheimer's disease
72. 3H]MK‐801 binding in Alzheimer's disease
73. The N‐methyl‐D‐aspartate receptor complex in Alzheimer's disease: reduced regulation by glycine but not zinc
74. Temporal lobe volumetric cell densities in temporal lobe epilepsy
75. Etiology and pathogenesis of temporal lobe epilepsy
76. Benzodiazepine receptor binding is not altered in human epileptogenic cortical foci
77. A selective N‐methyl‐D‐aspartate antagonist depresses epileptiform activity in rat hippocampal slices
78. Intracellular demonstration of an N‐methyl‐D‐aspartate receptor mediated component of synaptic transmission in rat hippocampus
79. NMDA receptors: what do they do?
80. N‐methyl‐D‐aspartate receptor antagonists reduce synaptic excitation in the hippocampus
81. Metabolic effects of prolonged epileptic seizures and their relation to nerve cell death
82. Ketamine and MK‐801 prevent degeneration of thalamic neurons induced by focal cortical seizures
83. Neurotransmitters in the regulation of neuronal cytoarchitecture